Career
Binmoeller relocated back to the United States after seven years in Hamburg, taking the position of Director of Endoscopy at the University of California at San Diego (UCSD) while holding a joint appointment as Associate Professor of Medicine and Science. [18] [17] Binmoeller is certified in gastroenterology and internal medicine by the American Board of Internal Medicine. [19]
He has been certified to practice in the states of:
Binmoeller was affiliated with the California Pacific Medical Center (CPMC) in San Francisco, CA, working as the Medical Director of the Interventional Endoscopy Services (IES). [18] His work in the field of endoscopic procedures is amongst the presentations of the New Frontiers Course, held annually. [23]
Binmoeller has been performing procedures in the field of interventional endoscopy since the 1980s. [24] [25] [12] Throughout his career as a medical specialist, he has also held university appointments in both Europe and the United States. These include:
In 2001, Binmoeller founded the Interventional Endoscopy Services (IES) at the CPMC, Van Ness Campus and Mission Bernal Campus. [27] This center was founded by Binmoeller, with him as acting Medical Director. The center's focus was on innovating and enabling new procedures in interventional endoscopy while improving existing techniques and technologies. [12] [28]
He has collaborated with multiple device manufacturers in an effort to improve existing products. He is also the clinical founder of several medical device start-ups:
- Advent - Offered a treatment for GERD (Gastroesophageal Reflux Disease). [29]
- Endeau - Founded in September 2012, techniques and devices were developed for underwater endoscopic procedures, or Water-Aided Endoscopy (WAE), aimed at systemizing the way WAE was used in gastroenterology procedures. Binmoeller was the Clinical Director. [30]
- Endosphere - Was responsible for multiple patents that enable the psychological treatment of metabolic diseases and obesity. Binmoeller is the inventor of the Satisphere™ [31] [32] duodenal implant under this startup, [33] a device that has undergone clinical trials. [34] [35]
- KB Solutions Inc. - Where the novel endoscopic tissue closure device was developed.
- Xlumena - Founded in 2004 by Binmoeller (Chief Medical Officer/Board Member) [36] with a portfolio of EUS guided translumenal therapy inventions. [21] [7]
Binmoeller is owner of over 100 Endoscopic Technology patents. [37] His first patent was filed in 1998 for an endosonographic guided tissue sampling device. [38] Development and global commercialization was assigned to the Olympus Medical Corporation, which brought the NA-11J-KB Powershot [39] needle to market. He is the inventor of the Lumen-Apposing Metal Stent (LAMS). His work on this was published in the Lumen-Apposing Stents, An Issue of Gastrointestinal Endoscopy Clinics, book. [40] [41] [25]
International Scholars Program (ISP)
ISP has mentored and trained multiple endoscopists from all across the globe [42] and launched a postgraduate program, The International Scholars Program in Advanced Endoscopy, in 2002 in collaboration with Sutter Health and California Pacific Medical Center. Binmoeller supervised a group of endoscopists and nurses, such as Dr. Janek Shah, Dr. Yasser Bhat, and Dr. Chris Hamerski. Its one-year training program reviews a broad spectrum of interventional endoscopic procedures, as well as various techniques like underwater resection of colonic polyps, endoscopic closure of gastrointestinal defects, and endoscopic therapy of subepithelial lesions, among other procedures. [25] [43] [44] Financial support for scholars is provided by Endovision for ISP. [45]
Non-Profit
The Endovision Foundation was Founded by Binmoeller in 2015 in San Francisco, California, [46] and he is the current President and Chief Executive Officer, overseeing management and direction. [47] [48]
The AXIOS System
Binmoeller invented the AXIOS system for advanced interventional endoscopy. This has two components, the AXIOS Stent and a cautery-enabled access catheter, to provide an Electrocautery Enhanced Delivery System. The system allows an endoscopist to access walled-off necrosis and symptomatic pancreatic pseudocysts by means of a transduodenal or a trans gastric approach to then place the AXIOS stent. [49]
This was the first system of its kind in the United States and is currently the only minimally invasive approach that entirely streamlines the process. [50] [51]
Xlumena acquired by Boston Scientific
In April 2015, Xlumena was acquired by Boston Scientific [52] when they agreed to pay $62.5 million with an additional $12.5 million for sales-based milestones [53] [54] upon FDA clearance of HOT AXIOS, [55] to go alongside the AXIOS Delivery System, [56] which had already received FDA 510(k) clearance [57] as the world’s first stent designed specifically for Endoscopic Ultrasound (EUS) guided transluminal drainage of symptomatic pancreatic pseudocysts. [58] [59] [60]
This page is based on this
Wikipedia article Text is available under the
CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
